Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Analyst Ratings for Sarepta Therapeutics
07:27pm, Thursday, 08'th Sep 2022 Benzinga
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
5
0
0
A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16%
05:31pm, Thursday, 08'th Sep 2022 Benzinga
Morgan Stanley raised the price target on Sarepta Therapeutics Inc (NASDAQ: SRPT) with an equal weight rating.
The analyst notes concerns regarding the Phase 3 EMBARK study, with a modest probabili
Clinical Hold on Sarepta's (SRPT) DMD Candidate Lifted by FDA
02:08pm, Wednesday, 07'th Sep 2022 Zacks Investment Research
The FDA lifts the clinical hold placed on Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, being evaluated in the ongoing phase II MOMENTUM study.
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year
12:30pm, Wednesday, 07'th Sep 2022 GlobeNewswire Inc.
- Recipients include 15 individuals living with Duchenne and five siblings in Duchenne families
Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
12:45pm, Tuesday, 06'th Sep 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will
Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
08:45am, Tuesday, 06'th Sep 2022
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will p
Mirati (MRTX) Up 5.3% Since Last Earnings Report: Can It Continue?
03:31pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Sarepta Therapeutics (SRPT) Up 13.8% Since Last Earnings Report?
03:31pm, Thursday, 01'st Sep 2022 Zacks Investment Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Sarepta Therapeutics (SRPT) Up 13.8% Since Last Earnings Report?
01:09pm, Thursday, 01'st Sep 2022
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:59pm, Wednesday, 31'st Aug 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 31, 2022 tha
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome
01:47pm, Tuesday, 30'th Aug 2022
In recent days, biotech stocks have slowed their early-August sprint. But not all shares are ready to hit the showers.
3 Biotech Stocks You Can Buy and Hold for the Next Decade
02:23pm, Monday, 29'th Aug 2022 The Motley Fool
All three companies are attempting to use unique discoveries to make marketable therapies.
Sarepta: Advancement In DMD Space With SRP-9001 And Licensed MyoAAV
04:09pm, Wednesday, 10'th Aug 2022
BLA filing of SRP-9001 for the treatment of patients with DMD is expected in fall of 2022; If filing and review go well then FDA Accelerated approval possible mid-2023. The global market opportunity f
Is Biotech Back? This Analyst Sees 18% Upside Potential In This Bio Play
03:55pm, Monday, 08'th Aug 2022 Benzinga
Sarepta Therapeutics Inc. (NASDAQ: SRPT), a pioneer in precision genetic medicine for rare diseases, announced Monday that it had signed licensing agreements with the Broad Institutes of both MIT and
Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts
06:20pm, Wednesday, 03'rd Aug 2022 Benzinga
Sarepta Therapeutics Inc (NASDAQ: SRPT) reported above-consensus 2Q FY22 product sales of $211 million and provided more details on the path forward for SRP-9001 gene therapy for Duchenne muscular
